Matinas BioPharma Holdings, Inc. (MTNB)
USD 0.53
(2.57%)
USD 0.53
(2.57%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 65.57 Million USD | 46.32% |
| 2022 | 44.81 Million USD | -26.92% |
| 2021 | 61.32 Million USD | -13.59% |
| 2020 | 70.96 Million USD | 76.36% |
| 2019 | 40.24 Million USD | 101.77% |
| 2018 | 19.94 Million USD | 38.27% |
| 2017 | 14.42 Million USD | 46.94% |
| 2016 | 9.81 Million USD | 16.78% |
| 2015 | 8.4 Million USD | 150.07% |
| 2014 | 3.36 Million USD | -70.34% |
| 2013 | 11.33 Million USD | 2570.76% |
| 2012 | 424.36 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 19.61 Million USD | -70.1% |
| 2024 Q2 | 24.36 Million USD | 24.25% |
| 2023 Q4 | 65.57 Million USD | 120.13% |
| 2023 Q1 | 38.26 Million USD | -14.63% |
| 2023 FY | 65.57 Million USD | 46.32% |
| 2023 Q2 | 34.02 Million USD | -11.07% |
| 2023 Q3 | 29.79 Million USD | -12.44% |
| 2022 FY | 44.81 Million USD | -26.92% |
| 2022 Q3 | 47.54 Million USD | -9.29% |
| 2022 Q2 | 52.41 Million USD | -6.04% |
| 2022 Q4 | 44.81 Million USD | -5.73% |
| 2022 Q1 | 55.78 Million USD | -9.04% |
| 2021 FY | 61.32 Million USD | -13.59% |
| 2021 Q1 | 72.35 Million USD | 1.95% |
| 2021 Q2 | 69.97 Million USD | -3.29% |
| 2021 Q4 | 61.32 Million USD | -8.45% |
| 2021 Q3 | 66.98 Million USD | -4.27% |
| 2020 Q3 | 74.8 Million USD | -5.41% |
| 2020 FY | 70.96 Million USD | 76.36% |
| 2020 Q1 | 84.11 Million USD | 109.03% |
| 2020 Q2 | 79.08 Million USD | -5.98% |
| 2020 Q4 | 70.96 Million USD | -5.13% |
| 2019 Q3 | 44.81 Million USD | -7.05% |
| 2019 Q4 | 40.24 Million USD | -10.21% |
| 2019 FY | 40.24 Million USD | 101.77% |
| 2019 Q1 | 50.57 Million USD | 153.58% |
| 2019 Q2 | 48.21 Million USD | -4.66% |
| 2018 Q1 | 11.48 Million USD | -20.34% |
| 2018 Q4 | 19.94 Million USD | 38.38% |
| 2018 FY | 19.94 Million USD | 38.27% |
| 2018 Q2 | 16.04 Million USD | 39.64% |
| 2018 Q3 | 14.41 Million USD | -10.17% |
| 2017 Q2 | 17.79 Million USD | -19.21% |
| 2017 FY | 14.42 Million USD | 46.94% |
| 2017 Q4 | 14.42 Million USD | -12.71% |
| 2017 Q3 | 16.52 Million USD | -7.17% |
| 2017 Q1 | 22.03 Million USD | 124.44% |
| 2016 Q2 | 5.56 Million USD | -17.51% |
| 2016 Q4 | 9.81 Million USD | -13.18% |
| 2016 FY | 9.81 Million USD | 16.78% |
| 2016 Q3 | 11.3 Million USD | 103.19% |
| 2016 Q1 | 6.74 Million USD | -19.75% |
| 2015 FY | 8.4 Million USD | 150.07% |
| 2015 Q3 | 9.86 Million USD | -16.8% |
| 2015 Q2 | 11.86 Million USD | 21.07% |
| 2015 Q1 | 9.79 Million USD | 191.47% |
| 2015 Q4 | 8.4 Million USD | -14.82% |
| 2014 Q1 | 9.32 Million USD | -17.71% |
| 2014 FY | 3.36 Million USD | -70.34% |
| 2014 Q4 | 3.36 Million USD | -41.93% |
| 2014 Q3 | 5.78 Million USD | -21.38% |
| 2014 Q2 | 7.36 Million USD | -21.05% |
| 2013 Q2 | 696.79 Thousand USD | 0.0% |
| 2013 Q1 | - USD | -100.0% |
| 2013 FY | 11.33 Million USD | 2570.76% |
| 2013 Q3 | 12.63 Million USD | 1712.68% |
| 2013 Q4 | 11.33 Million USD | -10.27% |
| 2012 FY | 424.36 Thousand USD | 0.0% |
| 2012 Q4 | 424.36 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 19.38 Million USD | -238.362% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | -1043.271% |
| Armata Pharmaceuticals, Inc. | 109.96 Million USD | 40.364% |
| Actinium Pharmaceuticals, Inc. | 81.44 Million USD | 19.482% |
| Azitra, Inc. | 5.11 Million USD | -1181.951% |
| Can-Fite BioPharma Ltd. | 9.98 Million USD | -556.502% |
| Chromocell Therapeutics Corporation | 96.39 Thousand USD | -67933.323% |
| Calidi Biotherapeutics, Inc. | 10.01 Million USD | -554.536% |
| CEL-SCI Corporation | 30.52 Million USD | -114.811% |
| iBio, Inc. | 28.73 Million USD | -128.224% |
| Lineage Cell Therapeutics, Inc. | 101.01 Million USD | 35.083% |
| MAIA Biotechnology, Inc. | 7.56 Million USD | -766.648% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -1400.089% |
| NovaBay Pharmaceuticals, Inc. | 9.03 Million USD | -625.902% |
| NanoViricides, Inc. | 12.82 Million USD | -411.415% |
| Oragenics, Inc. | 4.96 Million USD | -1220.451% |
| BiomX Inc. | 58.15 Million USD | -12.762% |
| BiomX Inc. | 58.15 Million USD | -12.762% |
| Protalix BioTherapeutics, Inc. | 84.43 Million USD | 22.332% |
| Palatin Technologies, Inc. | 10.74 Million USD | -510.467% |
| Scorpius Holdings, Inc. | 51.03 Million USD | -28.49% |
| Theriva Biologics, Inc. | 60.21 Million USD | -8.914% |